Myocyte enhancer factor (MEF2) Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A inhibits calcineurin, which when active can dephosphorylate and activate MEF2. Its inhibition thus prevents MEF2 activation. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H-89 is a potent inhibitor of PKA, which can phosphorylate MEF2. Inhibition of PKA leads to reduced MEF2 phosphorylation and activity. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB 216763 inhibits GSK-3β, which normally phosphorylates MEF2. However, in some contexts, GSK-3β activity may be required for MEF2 activation, so its inhibition could lead to decreased MEF2 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can influence multiple downstream signaling pathways, including those that may activate MEF2, leading to decreased activity. | ||||||
GW 9662 | 22978-25-2 | sc-202641 | 5 mg | $70.00 | 30 | |
GW9662 antagonizes PPARγ, possibly counteracting the activation effects on MEF2 signaling. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone, a glucocorticoid, can suppress various signaling pathways and alter gene expression, potentially downregulating MEF2 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAPK, which may indirectly influence MEF2 activity by modulating the signaling environment that regulates MEF2. | ||||||